Cocrystal Pharma, Inc. (COCP) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cocrystal Pharma, Inc., a Delaware corporation, on December 1, 2025. The report discloses a Regulation FD event regarding an upcoming investor presentation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material changes to financial position or operations are reported in this filing. The document solely announces a scheduled corporate event.
Guidance, Outlook, and Management Commentary
James Martin, Co-Chief Executive Officer and Chief Financial Officer, is scheduled to present a Company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025, at 10:00 am Eastern time. The press release accompanying this filing is furnished as Exhibit 99.1 but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the date and time of the Noble Capital Markets conference presentation (December 3, 2025, 10:00 am ET).
- Review the attached press release (Exhibit 99.1) for specific details on the clinical progress update.
- Confirm that no financial data is included in this specific 8-K filing.
- Monitor subsequent filings for any updates resulting from the conference presentation.